Kidney stones (also known as urinary stones or nephrolithiasis) are highly prevalent, affecting approximately 10% of adults worldwide, and the incidence of stone disease is increasing. Kidney stone formation results from an imbalance of inhibitors and promoters of crystallization, and calcium-containing calculi account for over 80% of stones. In most patients, the underlying aetiology is thought to be multifactorial, with environmental, dietary, hormonal and genetic components. The advent of high-throughput sequencing techniques has enabled a monogenic cause of kidney stones to be identified in up to 30% of children and 10% of adults who form stones, with ~35 different genes implicated. In addition, genome-wide association studies have implicated a series of genes involved in renal tubular handling of lithogenic substrates and of inhibitors of crystallization in stone disease in the general population. Such findings will likely lead to the identification of additional treatment targets involving underlying enzymatic or protein defects, including but not limited to those that alter urinary biochemistry.
Kidney stone disease is a complex phenotype that results from the interactions of multiple genes with dietary and environmental factors.
Advanced genetic testing modalities have enabled the identification of monogenic causes of kidney stones and nephrocalcinosis in select patients with severe phenotypes.
In the past decade, genome-wide association studies have implicated common gene variants in the pathogenesis of kidney stones; many of these variants are in genes that are mutated in monogenic stone disease.
In the future, genetic analyses could enable a personalized approach to the diagnosis and treatment of patients with rare and common varieties of kidney stones.
This is a preview of subscription content
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Scales, C. D. Jr, Smith, A. C., Hanley, J. M. & Saigal, C. S. Prevalence of kidney stones in the United States. Eur. Urol. 62, 160–165 (2012).
Tasian, G. E. et al. Annual incidence of nephrolithiasis among children and adults in South Carolina from 1997 to 2012. Clin. J. Am. Soc. Nephrol. 11, 488–496 (2016).
Stamatelou, K. K., Francis, M. E., Jones, C. A., Nyberg, L. M. & Curhan, G. C. Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int. 63, 1817–1823 (2003).
Romero, V., Akpinar, H. & Assimos, D. G. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev. Urol. 12, e86–e96 (2010).
Sorokin, I. et al. Epidemiology of stone disease across the world. World J. Urol. 35, 1301–1320 (2017).
Sas, D. J. An update on the changing epidemiology and metabolic risk factors in pediatric kidney stone disease. Clin. J. Am. Soc. Nephrol. 6, 2062–2068 (2011).
Dwyer, M. E. et al. Temporal trends in incidence of kidney stones among children: a 25-year population based study. J. Urol. 188, 247–252 (2012).
Lieske, J. C. et al. Renal stone epidemiology in Rochester, Minnesota: an update. Kidney Int. 69, 760–764 (2006).
Scales, C. D.Jr et al. Urinary stone disease: advancing knowledge, patient care, and population health. Clin. J. Am. Soc. Nephrol. 11, 1305–1312 (2016).
Rule, A. D. et al. Kidney stones and the risk for chronic kidney disease. Clin. J. Am. Soc. Nephrol. 4, 804–811 (2009).
Jeong, I. G. et al. Association between metabolic syndrome and the presence of kidney stones in a screened population. Am. J. Kidney Dis. 58, 383–388 (2011).
Reiner, A. P. et al. Kidney stones and subclinical atherosclerosis in young adults: the CARDIA study. J. Urol. 185, 920–925 (2011).
Dhondup, T. et al. Risk of ESRD and mortality in kidney and bladder stone formers. Am. J. Kidney Dis. 72, 790–797 (2018).
Rule, A. D., Krambeck, A. E. & Lieske, J. C. Chronic kidney disease in kidney stone formers. Clin. J. Am. Soc. Nephrol. 6, 2069–2075 (2011).
Ziemba, J. B. & Matlaga, B. R. Epidemiology and economics of nephrolithiasis. Investig. Clin. Urol. 58, 299–306 (2017).
Singh, P. et al. Stone composition among first-time symptomatic kidney stone formers in the community. Mayo Clin. Proc. 90, 1356–1365 (2015).
Coe, F. L., Worcester, E. M. & Evan, A. P. Idiopathic hypercalciuria and formation of calcium renal stones. Nat. Rev. Nephrol. 12, 519–533 (2016).
Evan, A. P. Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr. Nephrol. 25, 831–841 (2010).
Robertson, W. G., Peacock, M., Marshall, R. W., Marshall, D. H. & Nordin, B. E. C. Saturation-inhibition index as a measure of the risk of calcium oxalate stone formation in the urinary tract. N. Engl. J. Med. 294, 249–252 (1976).
Parks, J. H., Coward, M. & Coe, F. L. Correspondence between stone composition and urine supersaturation in nephrolithiasis. Kidney Int. 51, 894–900 (1997).
Finlayson, B. & Reid, S. The expectation of free and fixed particles in urinary stone disease. Invest. Urol. 15, 442–448 (1978).
Evan, A. P. et al. Mechanism of formation of human calcium oxalate renal stones on Randall’s plaque. Anat. Rec. 290, 1315–1323 (2007).
Randall, A. An hypothesis for the origin of renal calculus. N. Engl. J. Med 214, 234–242 (1936).
Khan, S. R. & Canales, B. K. Unified theory on the pathogenesis of Randall’s plaques and plugs. Urolithiasis 43 (Suppl 1), 109–123 (2015).
Evan, A. P. et al. Crystal-associated nephropathy in patients with brushite nephrolithiasis. Kidney Int. 67, 576–591 (2005).
Evan, A. P. et al. Renal crystal deposits and histopathology in patients with cystine stones. Kidney Int. 69, 2227–2235 (2006).
Evan, A. P., Worcester, E. M., Coe, F. L., Williams, J. Jr. & Lingeman, J. E. Mechanisms of human kidney stone formation. Urolithiasis 43 (Suppl 1), 19–32 (2015).
Coe, F. L., Evan, A. P., Worcester, E. M. & Lingeman, J. E. Three pathways for human kidney stone formation. Urological Res. 38, 147–160 (2010).
Evan, A. P. et al. Randall’s plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J. Clin. Invest. 111, 602–605 (2003).
Khan, S. R. et al. Kidney stones. Nat. Rev. Dis. Prim. 3, 17001 (2017).
Evan, A. P., Lingeman, J. E., Coe, F. L. & Worcester, E. M. Role of interstitial apatite plaque in the pathogenesis of the common calcium oxalate stone. Semin. Nephrol. 28, 111–119 (2008).
Chuang, T. F. et al. Risk of chronic kidney disease in patients with kidney stones — a nationwide cohort study. BMC Nephrol. 21, 292 (2020).
Jungers, P., Joly, D., Barbey, F., Choukroun, G. & Daudon, M. ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am. J. Kidney Dis. 44, 799–805 (2004).
Worcester, E. M., Parks, J. H., Evan, A. P. & Coe, F. L. Renal function in patients with nephrolithiasis. J. Urol. 176, 600–603 (2006). discussion 603.
Rule, A. D. et al. The association between benign prostatic hyperplasia and chronic kidney disease in community-dwelling men. Kidney Int. 67, 2376–2382 (2005).
Kersse, K., Bertrand, M. J., Lamkanfi, M. & Vandenabeele, P. NOD-like receptors and the innate immune system: coping with danger, damage and death. Cytokine Growth Factor. Rev. 22, 257–276 (2011).
Mulay, S. R. et al. Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1beta secretion. J. Clin. Invest. 123, 236–246 (2013).
Ware, E. B. et al. Genome-wide association study of 24-H urinary excretion of calcium, magnesium, and uric acid. Mayo Clin. Proc. Innov. Qual. Outcomes 3, 448–460 (2019).
Lieske, J. C. & Wang, X. Heritable traits that contribute to nephrolithiasis. Urolithiasis 47, 5–10 (2019).
Trinchieri, A., Mandressi, A., Luongo, P., Coppi, F. & Pisani, E. Familial aggregation of renal calcium stone disease. J. Urol. 139, 478–481 (1988).
Curhan, G. C., Willett, W. C., Rimm, E. B. & Stampfer, M. J. Family history and risk of kidney stones. J. Am. Soc. Nephrol. 8, 1568–1573 (1997).
Resnick, M., Pridgen, D. B. & Goodman, H. O. Genetic predisposition to formation of calcium oxalate renal calculi. N. Engl. J. Med. 278, 1313–1318 (1968).
McGeown, M. G. Heredity in renal stone disease. Clin. Sci. 19, 465–471 (1960).
Goldfarb, D. S., Fischer, M. E., Keich, Y. & Goldberg, J. A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) registry. Kidney Int. 67, 1053–1061 (2005).
Goldfarb, D. S., Avery, A. R., Beara-Lasic, L., Duncan, G. E. & Goldberg, J. A twin study of genetic influences on nephrolithiasis in women and men. Kidney Int. Rep. 4, 535–540 (2019).
Sayer, J. A. Progress in understanding the genetics of calcium-containing nephrolithiasis. J. Am. Soc. Nephrol. 28, 748–759 (2017).
Stechman, M. J., Loh, N. Y. & Thakker, R. V. Genetic causes of hypercalciuric nephrolithiasis. Pediatr. Nephrol. 24, 2321–2332 (2009).
Goldfarb, D. S. The exposome for kidney stones. Urolithiasis 44, 3–7 (2016).
Monico, C. G. & Milliner, D. S. Genetic determinants of urolithiasis. Nat. Rev. Nephrol. 8, 151–162 (2012).
Griffin, D. G. A review of the heritability of idiopathic nephrolithiasis. J. Clin. Pathol. 57, 793–796 (2004).
Hunter, D. J. et al. Genetic contribution to renal function and electrolyte balance: a twin study. Clin. Sci. 103, 259–265 (2002).
Whitfield, J. B. & Martin, N. G. The effects of inheritance on constituents of plasma: a twin study on some biochemical variables. Ann. Clin. Biochem. 21, 176–183 (1984).
Moulin, F. et al. A population-based approach to assess the heritability and distribution of renal handling of electrolytes. Kidney Int. 92, 1536–1543 (2017).
Ketha, H. et al. Altered calcium and vitamin d homeostasis in first-time calcium kidney stone-formers. PLoS One 10, e0137350 (2015).
Wjst, M., Altmuller, J., Braig, C., Bahnweg, M. & Andre, E. A genome-wide linkage scan for 25-OH-D(3) and 1,25-(OH)2-D3 serum levels in asthma families. J. Steroid Biochem. Mol. Biol. 103, 799–802 (2007).
Karohl, C. et al. Heritability and seasonal variability of vitamin D concentrations in male twins. Am. J. Clin. Nutr. 92, 1393–1398 (2010).
van Dongen, J., Willemsen, G., Chen, W. M., de Geus, E. J. & Boomsma, D. I. Heritability of metabolic syndrome traits in a large population-based sample. J. Lipid Res. 54, 2914–2923 (2013).
Coe, F. L. & Parks, J. H. in Nephrolithiasis: Pathogenesis and Treatment 108–138 (Year Book Medical Publishers, 1988).
Moe, O. W. & Bonny, O. Genetic hypercalciuria. J. Am. Soc. Nephrol. 16, 729–745 (2005).
Lieske, J. C., Turner, S. T., Edeh, S. N., Smith, J. A. & Kardia, S. L. Heritability of urinary traits that contribute to nephrolithiasis. Clin. J. Am. Soc. Nephrol. 9, 943–950 (2014).
Tessier, J. et al. A family-based study of metabolic phenotypes in calcium urolithiasis. Kidney Int. 60, 1141–1147 (2001).
Loredo-Osti, J. C. et al. Segregation of urine calcium excretion in families ascertained for nephrolithiasis: evidence for a major gene. Kidney Int. 68, 966–971 (2005).
Nicar, M. J., Skurla, C., Sakhaee, K. & Pak, C. Y. C. Low urinary citrate excretion in nephrolithiasis. Urology 21, 8–13 (1983).
Zuckerman, J. M. & Assimos, D. G. Hypocitraturia: pathophysiology and medical management. Rev. Urol. 11, 134–144 (2009).
Monga, M., Macias, B., Groppo, E. & Hargens, A. Genetic heritability of urinary stone risk in identical twins. J. Urol. 175, 2125–2128 (2006).
Taylor, E. N., Fung, T. T. & Curhan, G. C. DASH-style diet associates with reduced risk for kidney stones. J. Am. Soc. Nephrol. 20, 2253–2259 (2009).
Nouvenne, A. et al. Effects of a low-salt diet on idiopathic hypercalciuria in calcium-oxalate stone formers: a 3-mo randomized controlled trial. Am. J. Clin. Nutr. 91, 565–570 (2010).
Sorensen, M. D. et al. Dietary intake of fiber, fruit and vegetables decreases the risk of incident kidney stones in women: a Women’s Health Initiative report. J. Urol. 192, 1694–1699 (2014).
Lieske, J. C. et al. Heritability of dietary traits that contribute to nephrolithiasis in a cohort of adult sibships. J. Nephrol. 29, 45–51 (2016).
Martin, L. J., Lee, S. Y., Couch, S. C., Morrison, J. & Woo, J. G. Shared genetic contributions of fruit and vegetable consumption with BMI in families 20 y after sharing a household. Am. J. Clin. Nutr. 94, 1138–1143 (2011).
de Castro, J. M. A twin study of genetic and environmental influences on the intake of fluids and beverages. Physiol. Behav. 54, 677–687 (1993).
de Castro, J. M. Independence of genetic influences on body size, daily intake, and meal patterns of humans. Physiol. Behav. 54, 633–639 (1993).
Pearle, M. S. et al. Medical management of kidney stones: AUA guideline. J. Urol. 192, 316–324 (2014).
Rule, A. D., Lieske, J. C. & Pais, V. M. Jr Management of kidney stones in 2020. JAMA 323, 1961–1962 (2020).
Chillaron, J. et al. Pathophysiology and treatment of cystinuria. Nat. Rev. Nephrol. 6, 424–434 (2010).
Turk, C. et al. EAU guidelines on diagnosis and conservative management of urolithiasis. Eur. Urol. 69, 468–474 (2016).
Halbritter, J. et al. Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. J. Am. Soc. Nephrol. 26, 543–551 (2015).
Edvardsson, V. O. et al. Hereditary causes of kidney stones and chronic kidney disease. Pediatr. Nephrol. 28, 1923–1942 (2013).
Braun, D. A. et al. Prevalence of monogenic causes in pediatric patients with nephrolithiasis or nephrocalcinosis. Clin. J. Am. Soc. Nephrol. 11, 664–672 (2016).
Daga, A. et al. Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis. Kidney Int. 93, 204–213 (2018).
Dent, C. E. & Friedman, M. Hypercalciuric rickets associated with renal tubular damage. Arch. Dis. Child. 39, 240–249 (1964).
Thakker, R. V. Pathogenesis of Dent’s disease and related syndromes of X-linked nephrolithiasis. Kidney Int. 57, 787–793 (2000).
Pook, M. A. et al. Dent’s disease, a renal Fanconi syndrome and nephrocalcinosis and kidney stones, is associated with a microdeletion involving DXS255 and maps to Xp11.22 by linkage studies. Hum. Mol. Genet. 2, 2129–2134 (1993).
Dickson, F. J. & Sayer, J. A. Nephrocalcinosis: a review of monogenic causes and insights they provide into this heterogeneous condition. Int. J. Mol. Sci. 21, 369 (2020).
Ehlayel, A. M. & Copelovitch, L. Update on Dent disease. Pediatr. Clin. North. Am. 66, 169–178 (2019).
Claverie-Martin, F., Ramos-Trujillo, E. & Garcia-Nieto, V. Dent’s disease: clinical features and molecular basis. Pediatr. Nephrol. 26, 693–704 (2011).
Lieske, J. C. et al. in GeneReviews® (eds Adam, M. P. et al.) (University of Washington, 1993).
Bockenhauer, D. et al. Renal phenotype in Lowe Syndrome: a selective proximal tubular dysfunction. Clin. J. Am. Soc. Nephrol. 3, 1430–1436 (2008).
De Matteis, M. A., Staiano, L., Emma, F. & Devuyst, O. The 5-phosphatase OCRL in Lowe syndrome and Dent disease 2. Nat. Rev. Nephrol. 13, 455–470 (2017).
Devuyst, O. & Thakker, R. V. Dent’s disease. Orphanet J. Rare Dis. 5, 28 (2010).
Bokenkamp, A. et al. Dent-2 disease: a mild variant of Lowe syndrome. J. Pediatr. 155, 94–99 (2009).
Blanchard, A. et al. Observations of a large Dent disease cohort. Kidney Int. 90, 430–439 (2016).
Prikhodina, L., Papizh, S., Bashirova, Z. & Ludwig, M. Whether women asymptomatic or symptomatic carriers of dent disease? Nephrol. Dial. Transpl. 33, 303 (2018).
Wrong, O. M., Norden, A. G. W. & Feest, T. G. Dent’s disease; a familial proximal renal tubular syndrome with low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic bone disease, progressive renal failure and marked male predominance. Q. J. Med. 87, 473–493 (1994).
Mansour-Hendili, L. et al. Mutation update of the CLCN5 gene responsible for Dent disease 1. Hum. Mutat. 36, 743–752 (2015).
Pusch, M. & Zifarelli, G. ClC-5: physiological role and biophysical mechanisms. Cell Calcium 58, 57–66 (2015).
Nielsen, R., Christensen, E. I. & Birn, H. Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease. Kidney Int. 89, 58–67 (2016).
Wang, S. S. et al. Mice lacking renal chloride channel, CLC-5, are a model for Dent’s disease, a nephrolithiasis disorder associated with defective receptor-mediated endocytosis. Hum. Mol. Genet. 9, 2937–2945 (2000).
Levin-Iaina, N. & Dinour, D. Renal disease with OCRL1 mutations: Dent-2 or Lowe syndrome? J. Pediatr. Genet. 1, 3–5 (2012).
Suchy, S. F. & Nussbaum, R. L. The deficiency of PIP2 5-phosphatase in Lowe syndrome affects actin polymerization. Am. J. Hum. Genet. 71, 1420–1427 (2002).
Blanchard, A. et al. Effect of hydrochlorothiazide on urinary calcium excretion in Dent disease: an uncontrolled trial. Am. J. Kidney Dis. 52, 1084–1095 (2008).
Konrad, M. et al. Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am. J. Hum. Genet. 79, 949–957 (2006).
Simon, D. B. et al. Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption. Science 285, 103–106 (1999).
Weber, S. et al. Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J. Am. Soc. Nephrol. 12, 1872–1881 (2001).
Haisch, L., Almeida, J. R., Abreu da Silva, P. R., Schlingmann, K. P. & Konrad, M. The role of tight junctions in paracellular ion transport in the renal tubule: lessons learned from a rare inherited tubular disorder. Am. J. Kidney Dis. 57, 320–330 (2011).
Godron, A. et al. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis: phenotype-genotype correlation and outcome in 32 patients with CLDN16 or CLDN19 mutations. Clin. J. Am. Soc. Nephrol. 7, 801–809 (2012).
Hampson, G., Konrad, M. A. & Scoble, J. Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis (FHHNC): compound heterozygous mutation in the claudin 16 (CLDN16) gene. BMC Nephrol. 9, 12 (2008).
Arteaga, M. E., Hunziker, W., Teo, A. S., Hillmer, A. M. & Mutchinick, O. M. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis: variable phenotypic expression in three affected sisters from Mexican ancestry. Ren. Fail. 37, 180–183 (2015).
Claverie-Martin, F. Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis: clinical and molecular characteristics. Clin. Kidney J. 8, 656–664 (2015).
Gong, Y. et al. Claudin-14 regulates renal Ca++ transport in response to CaSR signalling via a novel microRNA pathway. EMBO J. 31, 1999–2012 (2012).
Hou, J. Lecture: new light on the role of claudins in the kidney. Organogenesis 8, 1–9 (2012).
Karet, F. E. Inherited distal renal tubular acidosis. J. Am. Soc. Nephrol. 13, 2178–2184 (2002).
Alexander, R. T., Law, L., Gil-Pena, H., Greenbaum, L. A. & Santos, F. in GeneReviews® (eds M. P. Adam et al.) (1993).
Rungroj, N. et al. Distal renal tubular acidosis caused by tryptophan-aspartate repeat domain 72 (WDR72) mutations. Clin. Genet. 94, 409–418 (2018).
Jobst-Schwan, T. et al. Whole exome sequencing identified ATP6V1C2 as a novel candidate gene for recessive distal renal tubular acidosis. Kidney Int. 97, 567–579 (2020).
Watanabe, T. Improving outcomes for patients with distal renal tubular acidosis: recent advances and challenges ahead. Pediatr. Health Med. Ther. 9, 181–190 (2018).
Besouw, M. T. P. et al. Clinical and molecular aspects of distal renal tubular acidosis in children. Pediatr. Nephrol. 32, 987–996 (2017).
Enerback, S. et al. Acidosis and deafness in patients with recessive mutations in FOXI1. J. Am. Soc. Nephrol. 29, 1041–1048 (2018).
D’Ambrosio, V. et al. Results of a gene panel approach in a cohort of patients with incomplete distal renal tubular acidosis and nephrolithiasis. Kidney Blood Press. Res. 46, 469–474 (2021).
Zhang, J. et al. Incomplete distal renal tubular acidosis from a heterozygous mutation of the V-ATPase B1 subunit. Am. J. Physiol. Renal Physiol. 307, F1063–F1071 (2014).
Bourgeois, S., Bettoni, C., Baron, S. & Wagner, C. A. Haploinsufficiency of the Mouse Atp6v1b1 gene leads to a mild acid-base disturbance with implications for kidney stone disease. Cell Physiol. Biochem. 47, 1095–1107 (2018).
Park, E. et al. Genotype-phenotype analysis in pediatric patients with distal renal tubular acidosis. Kidney Blood Press. Res. 43, 513–521 (2018).
Sly, W. S. et al. Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. N. Engl. J. Med. 313, 139–145 (1985).
Venta, P. J., Welty, R. J., Johnson, T. M., Sly, W. S. & Tashian, R. E. Carbonic anhydrase II deficiency syndrome in a Belgian family is caused by a point mutation at an invariant histidine residue (107 His — Tyr): complete structure of the normal human CA II gene. Am. J. Hum. Genet. 49, 1082–1090 (1991).
Whyte, M. P. Carbonic anhydrase II deficiency. Clin. Orthop. Relat. Res. 52–63 (1993).
Bergwitz, C. & Miyamoto, K. I. Hereditary hypophosphatemic rickets with hypercalciuria: pathophysiology, clinical presentation, diagnosis and therapy. Pflugers Arch. 471, 149–163 (2019).
Lorenz-Depiereux, B. et al. Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am. J. Hum. Genet. 78, 193–201 (2006).
Dasgupta, D. et al. Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis. J. Am. Soc. Nephrol. 25, 2366–2375 (2014).
Tieder, M. et al. Hereditary hyporphosphatemic rickets with hypercalciuria. N. Engl. J. Med. 312, 611–617 (1985).
Schlingmann, K. P. et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N. Engl. J. Med. 365, 410–421 (2011).
De Paolis, E., Scaglione, G. L., De Bonis, M., Minucci, A. & Capoluongo, E. CYP24A1 and SLC34A1 genetic defects associated with idiopathic infantile hypercalcemia: from genotype to phenotype. Clin. Chem. Lab. Med. 57, 1650–1667 (2019).
Tebben, P. J. et al. Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy. J. Clin. Endocrinol. Metab. 97, E423–E427 (2012).
Tebben, P. J., Singh, R. J. & Kumar, R. Vitamin D-mediated hypercalcemia: mechanisms, diagnosis, and treatment. Endocr. Rev. 37, 521–547 (2016).
Carpenter, T. O. Take another CYP: confirming a novel mechanism for “idiopathic” hypercalcemia. J. Clin. Endocrinol. Metab. 97, 768–771 (2012).
Nesterova, G. et al. 1,25-(OH)2D-24 hydroxylase (CYP24A1) deficiency as a cause of nephrolithiasis. Clin. J. Am. Soc. Nephrol. 8, 649–657 (2013).
Schlingmann, K. P., Cassar, W. & Konrad, M. Juvenile onset IIH and CYP24A1 mutations. Bone Rep. 9, 42–46 (2018).
Hawkes, C. P. et al. CYP3A4 induction by rifampin: an alternative pathway for Vitamin D inactivation in patients with CYP24A1 mutations. J. Clin. Endocrinol. Metab. 102, 1440–1446 (2017).
Sayers, J. Adrian Stokes and the portrait of Melanie Klein. Int. J. Psychoanal. 96, 1013–1024 (2015).
Schlingmann, K. P. et al. Autosomal-recessive mutations in SLC34A1 encoding sodium-phosphate cotransporter 2A cause idiopathic infantile hypercalcemia. J. Am. Soc. Nephrol. 27, 604–614 (2016).
Wagner, C. A., Rubio-Aliaga, I. & Hernando, N. Renal phosphate handling and inherited disorders of phosphate reabsorption: an update. Pediatr. Nephrol. 34, 549–559 (2019).
Amar, A. et al. Gene panel sequencing identifies a likely monogenic cause in 7% of 235 Pakistani families with nephrolithiasis. Hum. Genet. 138, 211–219 (2019).
Kang, S. J., Lee, R. & Kim, H. S. Infantile hypercalcemia with novel compound heterozygous mutation in SLC34A1 encoding renal sodium-phosphate cotransporter 2a: a case report. Ann. Pediatr. Endocrinol. Metab. 24, 64–67 (2019).
Policastro, L. J., Saggi, S. J., Goldfarb, D. S. & Weiss, J. P. Personalized intervention in monogenic stone formers. J. Urol. 199, 623–632 (2018).
Oliveira, B., Kleta, R., Bockenhauer, D. & Walsh, S. B. Genetic, pathophysiological, and clinical aspects of nephrocalcinosis. Am. J. Physiol. Renal Physiol. 311, F1243–F1252 (2016).
Simon, D. B. et al. Genetic heterogeneity of Bartter’s syndrome revealed by mutations in the K+ channel, ROMK. Nat. Genet. 14, 152–156 (1996).
Simon, D. B. et al. Bartter’s syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat. Genet. 13, 183–188 (1996).
Gollasch, B., Anistan, Y. M., Canaan-Kuhl, S. & Gollasch, M. Late-onset Bartter syndrome type II. Clin. Kidney J. 10, 594–599 (2017).
Huang, L. et al. Nephrocalcinosis as adult presentation of Bartter syndrome type II. Neth. J. Med. 72, 91–93 (2014).
Simon, D. B. et al. Mutations in the chloride channel gene, CLCNKB, cause Bartter’s syndrome type III. Nat. Genet. 17, 171–178 (1997).
Brochard, K. et al. Phenotype-genotype correlation in antenatal and neonatal variants of Bartter syndrome. Nephrol. Dial. Transpl. 24, 1455–1464 (2009).
Jeck, N. et al. Hypokalemic salt-losing tubulopathy with chronic renal failure and sensorineural deafness. Pediatrics 108, E5 (2001).
Schlingmann, K. P. et al. Salt wasting and deafness resulting from mutations in two chloride channels. N. Engl. J. Med. 350, 1314–1319 (2004).
Laghmani, K. et al. Polyhydramnios, transient antenatal Bartter’s syndrome, and MAGED2 mutations. N. Engl. J. Med. 374, 1853–1863 (2016).
Pearce, S. H. S. et al. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N. Engl. J. Med. 335, 1115–1122 (1996).
Hannan, F. M. et al. Identification of 70 calcium-sensing receptor mutations in hyper- and hypo-calcaemic patients: evidence for clustering of extracellular domain mutations at calcium-binding sites. Hum. Mol. Genet. 21, 2768–2778 (2012).
Hannan, F. M., Kallay, E., Chang, W., Brandi, M. L. & Thakker, R. V. The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nat. Rev. Endocrinol. 15, 33–51 (2018).
Hannan, F. M. & Thakker, R. V. Calcium-sensing receptor (CaSR) mutations and disorders of calcium, electrolyte and water metabolism. Best. Pract. Res. Clin. Endocrinol. Metab. 27, 359–371 (2013).
Hussain, A., Atlani, M., Goyal, A. & Khurana, A. K. Type-5 Bartter syndrome presenting with metabolic seizure in adulthood. BMJ Case Rep. 14, e235349 (2021).
Nesbit, M. A. et al. Mutations affecting G-protein subunit alpha11 in hypercalcemia and hypocalcemia. N. Engl. J. Med. 368, 2476–2486 (2013).
Cochat, P. & Rumsby, G. Primary hyperoxaluria. N. Engl. J. Med. 369, 649–658 (2013).
Hoppe, B. An update on primary hyperoxaluria. Nat. Rev. Nephrol. 8, 467–475 (2012).
Lieske, J. C., Spargo, B. H. & Toback, F. G. Endocytosis of calcium oxalate crystals and proliferation of renal tubular epithelial cells in a patient with type 1 primary hyperoxaluria. J. Urol. 148, 1517–1519 (1992).
Milliner, D. S., Harris, P. C., Cogal, A. G. & Lieske, J. C. in GeneReviews® (eds M. P. Adam et al.) (1993).
Danpure, C. J. Molecular etiology of primary hyperoxaluria type 1: new directions for treatment. Am. J. Nephrol. 25, 303–310 (2005).
Hopp, K. et al. Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J. Am. Soc. Nephrol. 26, 2559–2570 (2015).
Danpure, C. J. Primary hyperoxaluria type 1: AGT mistargeting highlights the fundamental differences between the peroxisomal and mitochondrial protein import pathways. Biochim. Biophys. Acta 1763, 1776–1784 (2006).
Martin-Higueras, C., Torres, A. & Salido, E. Molecular therapy of primary hyperoxaluria. J. Inherit. Metab. Dis. 40, 481–489 (2017).
Fargue, S., Lewin, J., Rumsby, G. & Danpure, C. J. Four of the most common mutations in primary hyperoxaluria type 1 unmask the cryptic mitochondrial targeting sequence of alanine:glyoxylate aminotransferase encoded by the polymorphic minor allele. J. Biol. Chem. 288, 2475–2484 (2013).
Beck, B. B., Hoyer-Kuhn, H., Gobel, H., Habbig, S. & Hoppe, B. Hyperoxaluria and systemic oxalosis: an update on current therapy and future directions. Expert Opin. Investig. Drugs 22, 117–129 (2013).
Monico, C. G., Olson, J. B. & Milliner, D. S. Implications of genotype and enzyme phenotype in pyridoxine response of patients with type I primary hyperoxaluria. Am. J. Nephrol. 25, 183–188 (2005).
Singh, P. et al. Pyridoxine responsiveness in a type 1 primary hyperoxaluria patient with a rare (atypical) AGXT gene mutation. Kidney Int. Rep. 5, 955–958 (2020).
Cramer, S. D., Ferree, P. M., Lin, K., Milliner, D. S. & Holmes, R. P. The gene encoding hydroxypyruvate reductase (GRHPR) is mutated in patients with primary hyperoxaluria type II [published erratum appears in Hum Mol Genet 1999 Dec;8(13):2574]. Hum. Mol. Genet. 8, 2063–2069 (1999).
Garrelfs, S. F. et al. Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. Kidney Int. 96, 1389–1399 (2019).
Milliner, D. S., Wilson, D. M. & Smith, L. H. Phenotypic expression of primary hyperoxaluria: comparative features of types I and II. Kidney Int. 59, 31–36 (2001).
Milliner, D. S., Harris, P. C. & Lieske, J. C. in GeneReviews® (eds M. P. Adam et al.) (1993).
Beck, B. B. et al. Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. Eur. J. Hum. Genet. 21, 162–172 (2013).
Belostotsky, R. et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am. J. Hum. Genet. 87, 392–399 (2010).
Ventzke, A. et al. Systematic assessment of urinary hydroxy-oxo-glutarate for diagnosis and follow-up of primary hyperoxaluria type III. Pediatr. Nephrol. 32, 2263–2271 (2017).
Greed, L. et al. Metabolite diagnosis of primary hyperoxaluria type 3. Pediatr. Nephrol. 33, 1443–1446 (2018).
Allard, L. et al. Renal function can be impaired in children with primary hyperoxaluria type 3. Pediatr. Nephrol. 30, 1807–1813 (2015).
Compagnon, P. et al. Long-term results of combined liver-kidney transplantation for primary hyperoxaluria type 1: the French experience. Liver Transpl. 20, 1475–1485 (2014).
Weigert, A., Martin-Higueras, C. & Hoppe, B. Novel therapeutic approaches in primary hyperoxaluria. Expert Opin. Emerg. Drugs 23, 349–357 (2018).
Hulton, S. A. The primary hyperoxalurias: a practical approach to diagnosis and treatment. Int. J. Surg. 36, 649–654 (2016).
Knoll, T., Zollner, A., Wendt-Nordahl, G., Michel, M. S. & Alken, P. Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up. Pediatr. Nephrol. 20, 19–24 (2005).
Calonge, M. J. et al. Cystinuria caused by mutations in rBAT, a gene involved in the transport of cystine. Nat. Genet. 6, 420–425 (1994).
Feliubadalo, L. et al. Non-type I cystinuria caused by mutations in SLC7A9, encoding a subunit (bo,+AT) of rBAT. Nat. Genet. 23, 52–57 (1999).
Rhodes, H. L. et al. Clinical and genetic analysis of patients with cystinuria in the United Kingdom. Clin. J. Am. Soc. Nephrol. 10, 1235–1245 (2015).
Chow, G. K. & Streem, S. B. Medical treatment of cystinuria: results of contemporary clinical practice. J. Urol. 156, 1576–1578 (1996).
Bollee, G. et al. Phenotype and genotype characterization of adenine phosphoribosyltransferase deficiency. J. Am. Soc. Nephrol. 21, 679–688 (2010).
Runolfsdottir, H. L., Palsson, R., Agustsdottir, I. M., Indridason, O. S. & Edvardsson, V. O. Kidney disease in adenine phosphoribosyltransferase deficiency. Am. J. Kidney Dis. 67, 431–438 (2016).
Edvardsson, V., Palsson, R., Olafsson, I., Hjaltadottir, G. & Laxdal, T. Clinical features and genotype of adenine phosphoribosyltransferase deficiency in Iceland. Am. J. Kidney Dis. 38, 473–480 (2001).
Kamatani, N., Hakoda, M., Otsuka, S., Yoshikawa, H. & Kashiwazaki, S. Only three mutations account for almost all defective alleles causing adenine phosphoribosyltransferase deficiency in Japanese patients. J. Clin. Invest. 90, 130–135 (1992).
Harambat, J., Bollee, G., Daudon, M., Ceballos-Picot, I. & Bensman, A. Adenine phosphoribosyltransferase deficiency in children. Pediatr. Nephrol. 27, 571–579 (2012).
Edvardsson, V. O. et al. Comparison of the effect of allopurinol and febuxostat on urinary 2,8-dihydroxyadenine excretion in patients with adenine phosphoribosyltransferase deficiency (APRTd): a clinical trial. Eur. J. Intern. Med. 48, 75–79 (2018).
Ichida, K. et al. Identification of two mutations in human xanthine dehydrogenase gene responsible for classical type I xanthinuria. J. Clin. Invest. 99, 2391–2397 (1997).
Ichida, K., Matsumura, T., Sakuma, R., Hosoya, T. & Nishino, T. Mutation of human molybdenum cofactor sulfurase gene is responsible for classical xanthinuria type II. Biochem. Biophys. Res. Commun. 282, 1194–1200 (2001).
Zaki, M. S. et al. Molybdenum cofactor and isolated sulphite oxidase deficiencies: clinical and molecular spectrum among Egyptian patients. Eur. J. Paediatr. Neurol. 20, 714–722 (2016).
Nagae, A. et al. Asymptomatic hereditary xanthinuria: a case report. Jpn. J. Med. 29, 287–291 (1990).
Reiss, J. & Hahnewald, R. Molybdenum cofactor deficiency: mutations in GPHN, MOCS1, and MOCS2. Hum. Mutat. 32, 10–18 (2011).
Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. Nat. Rev. Urol. 17, 407–421 (2020).
Thorleifsson, G. et al. Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat. Genet. 41, 926–930 (2009).
Oddsson, A. et al. Common and rare variants associated with kidney stones and biochemical traits. Nat. Commun. 6, 7975 (2015).
Palsson, R., Indridason, O. S., Edvardsson, V. O. & Oddsson, A. Genetics of common complex kidney stone disease: insights from genome-wide association studies. Urolithiasis 47, 11–21 (2019).
Curry, J. N. et al. Claudin-2 deficiency associates with hypercalciuria in mice and human kidney stone disease. J. Clin. Invest. 130, 1948–1960 (2020).
Muto, S. et al. Claudin-2-deficient mice are defective in the leaky and cation-selective paracellular permeability properties of renal proximal tubules. Proc. Natl Acad. Sci. USA 107, 8011–8016 (2010).
Worcester, E. M. et al. Evidence for increased postprandial distal nephron calcium delivery in hypercalciuric stone-forming patients. Am. J. Physiol. Renal Physiol. 295, F1286–F1294 (2008).
Devuyst, O., Olinger, E. & Rampoldi, L. Uromodulin: from physiology to rare and complex kidney disorders. Nat. Rev. Nephrol. 13, 525–544 (2017).
Gudbjartsson, D. F. et al. Association of variants at UMOD with chronic kidney disease and kidney stones-role of age and comorbid diseases. PLoS Genet. 6, e1001039 (2010).
Devuyst, O. et al. Autosomal dominant tubulointerstitial kidney disease. Nat. Rev. Dis. Prim. 5, 60 (2019).
Hoenderop, J. G. et al. Renal Ca2+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5. J. Clin. Invest. 112, 1906–1914 (2003).
Hoenderop, J. G. J. et al. Localization of the epithelial Ca2+ channel in rabbit kidney and intestine. J. Am. Soc. Nephrol. 11, 1171–1178 (2000).
Moor, M. B. & Bonny, O. Ways of calcium reabsorption in the kidney. Am. J. Physiol. Renal Physiol. 310, F1337–F1350 (2016).
Urabe, Y. et al. A genome-wide association study of nephrolithiasis in the Japanese population identifies novel susceptible Loci at 5q35.3, 7p14.3, and 13q14.1. PLoS Genet. 8, e1002541 (2012).
Li, X. et al. Common variants in ALPL gene contribute to the risk of kidney stones in the Han Chinese population. Genet. Test. Mol. Biomark. 22, 187–192 (2018).
Howles, S. A. et al. Genetic variants of calcium and vitamin D metabolism in kidney stone disease. Nat. Commun. 10, 5175 (2019).
Paranjpe, I. et al. Derivation and validation of genome-wide polygenic score for urinary tract stone diagnosis. Kidney Int. 98, 1323–1330 (2020).
Zaidi, S. K. et al. Mitotic bookmarking of genes: a novel dimension to epigenetic control. Nat. Rev. Genet. 11, 583–589 (2010).
J.C.L. receives consulting fees from the American Board of Internal Medicine, Alnylam, OxThera, Dicerna, Synlogic, Orfan and Novobiome, and grant support from Alnylam, Allena, Retrophin, OxThera, NIDDK and Dicerna. D.J.S. has received consulting fees from Advicenne, and lecture fees from Retrophin. P.C.H. receives consulting fees from Otsuka Pharmaceuticals, Mitobridge, Regulus, Vertex Pharmaceuticals and Caraway Therapeutics. He has received grant support from Otsuka Pharmaceuticals, Navitor, Acceleron and Jemincare. P.S. has no competing interests.
Peer review information
Nature Reviews Nephrology thanks Paul Goodyer; John Sayer, who co-reviewed with Eric Olinger; and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Singh, P., Harris, P.C., Sas, D.J. et al. The genetics of kidney stone disease and nephrocalcinosis. Nat Rev Nephrol 18, 224–240 (2022). https://doi.org/10.1038/s41581-021-00513-4
Nature Reviews Endocrinology (2022)